Study of Antithymocyte Globulin for Treatment of New-onset T1DM
Status:
Terminated
Trial end date:
2013-07-01
Target enrollment:
Participant gender:
Summary
Antithymocyte globulin (e.g., Thymoglobulin®) is an antibody preparation that is commonly
used to treat and prevent organ transplant rejection. The START trial aims to determine
whether antithymocyte globulin (ATG) treatment can halt the progression of newly diagnosed
type 1 diabetes when given within 12 weeks of disease diagnosis.
Phase:
Phase 2
Details
Lead Sponsor:
National Institute of Allergy and Infectious Diseases (NIAID)